Tomáš Cihlář is the Senior Vice President of Research, Virology at Gilead Sciences, where he leads the Department of Biology with a team of hundreds of scientists who are developing antivirals for the treatment of HIV, hepatitis B, respiratory infections and other viral diseases such as Ebola, MERS and dengue fever. At Gilead Sciences, he was involved in the development of remdesivir, originally designed to treat Ebola. Remdesivir has proven to be effective in the supportive treatment of coronavirus infection. Tomáš Cihlář received the Extraordinary Neuron Award on 28 September 2020 for significant scientific discovery and contributions to the development of virostatics against serious viral diseases and for contributions to Czech and world science.